AGP Executive Report
Last update: 18 hours agoCancer Research in NJ: Bristol Myers Squibb reported late-breaking Phase 3 results at ASCO showing its oral multiple myeloma drug mezigdomide (MeziKd) cut the risk of progression or death by 52% versus standard carfilzomib/dexamethasone, with median progression-free survival rising to 18 months. Prostate Cancer & Brain Health: In a New Jersey-linked Phase II head-to-head trial, Bayer’s NUBEQA (darolutamide) showed less decline in objective cognitive performance over 24 weeks than enzalutamide for men with advanced prostate cancer. AI Backlash Hits NJ: A new Gallup poll finds 71% of Americans oppose AI data center construction locally, echoing mounting community fights over power, water, and utility bills. World Cup Security Tech: The FBI is training regional teams for an anti-drone taskforce to protect fans amid fears of drone misuse at major events. Aviation Innovation: Electra completed the first urban demo of its hybrid-electric ultra-short aircraft, aiming to bring regional flights closer to where people live. Public Safety: A Spalding County arrest in Georgia charges a man with a 1989 Bayonne homicide, pending extradition to New Jersey.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
